Avidity Partners Management LP Gritstone Bio, Inc. Transaction History

Avidity Partners Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.19 - $2.26 $37,723 - $71,642	-31,700 Reduced 1.15%	2,733,800 $4.7 Million
Q2 2023 Aug 14, 2023	BUY	$1.66 - $3.03 $4.59 Million - $8.38 Million	2,765,500 New	2,765,500 $5.39 Million
Q2 2022 Aug 15, 2022	SELL	$1.77 - $4.34 $991,200 - $2.43 Million	-560,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.03 - $12.19 $15.4 Million - $46.4 Million	-3,810,000 Reduced 87.19%	560,000 $2.31 Million
Q4 2021 Feb 14, 2022	SELL	$8.76 - $13.71 $769,399 - $1.2 Million	-87,831 Reduced 1.97%	4,370,000 $56.2 Million
Q3 2021 Nov 15, 2021	BUY	$6.41 - $13.54 $15 Million - $31.6 Million	2,335,767 Added 110.07%	4,457,831 $48.1 Million
Q4 2020 Feb 16, 2021	BUY	$2.57 - $4.22 $5.45 Million - $8.96 Million	2,122,064 New	2,122,064 $8.36 Million

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.